Invasive pneumococcal disease in Australia, 2009 and 2010
DOI:
https://doi.org/10.33321/cdi.2015.39.23Keywords:
Australia, invasive pneumococcal disease, communicable disease surveillance, epidemiology, annual reportAbstract
Enhanced surveillance for invasive pneumococcal disease (IPD) was conducted in all Australian states and territories in 2009 and 2010 with comprehensive comparative data available since 2002. There were 1,556 cases of IPD notified to the National Notifiable Diseases Surveillance System in Australia in 2009, a notification rate of 7.2 cases per 100,000 population. In 2010 there were 1,640 cases, a notification rate of 7.4 cases per 100,000. The overall rate of IPD in Indigenous Australians was almost 6 times the rate in non-Indigenous Australians in both 2009 and 2010. In 2009 and 2010, notification rates of IPD caused by serotypes included in the 7-valent pneumococcal conjugate vaccine (7vPCV) continued to decrease across all age groups. Rates of IPD caused by non-7vPCV serotypes continued to show an increasing trend in both Indigenous and non-Indigenous children aged less than 5 years. In Indigenous adults (≥50 years), rates of IPD caused by both 23-valent pneumococcal polysaccharide vaccine (23vPPV) serotypes and non-23vPPV serotypes continued to show an overall increase, particularly in 2010. There were 110 deaths attributed to IPD in 2009 and 137 in 2010, although it should be noted that deaths may be under-reported. The number of invasive pneumococcal isolates with reduced penicillin susceptibility remained low and reduced susceptibility to third generation cephalosporins was rare. Commun Dis Intell 2015;39(2):E265–E279.
Downloads
References
Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59(RR–11):1–18.
Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, Hadler JL, et al. Bacterial meningitis in the United States, 1998–2007. N Engl J Med 2011;364(21):2016–2025.
Chiu C, Dey A, Wang H, Menzies R, Deeks S, Mahajan D, et al. Vaccine Preventable Diseases in Australia, 2005 to 2007. Commun Dis Intell 2010;34(Suppl):S1–S172.
Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. 10th edn. Canberra, Australia: National Health and Medical Research Council and the Department of Health and Ageing; 2013.
Roche P, Krause V, Andrews R, Carter L, Coleman D, Cook H, et al. Invasive pneumococcal disease in Australia, 2002. Commun Dis Intell 2003;27(2):466–477.
Roche P, Krause V, Bartlett M, Coleman D, Cook H, Counahan M, et al. Invasive pneumococcal disease in Australia, 2003. Commun Dis Intell 2004;28(4):441–454.
Roche P, Krause V, Bartlett B, Coleman D, Cook H, Davis C, et al. Invasive pneumococcal disease in Australia, 2004. Commun Dis Intell 2006;30(1):80–92.
Roche P, Krause V, Cook H. Invasive pneumococcal disease in Australia, 2005. Commun Dis Intell 2007;31(1):86–100.
Roche P, Krause V, Cook H, Bartlett M, Coleman D, Davis C, et al. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 2008;32(1):18–30.
Barry C, Krause VL, Cook HM, Menzies RI. Invasive pneumococcal disease in Australia 2007 and 2008. Commun Dis Intell 2012;36(2):E151–E165.
National Health Security Act, 2007. Accessed on November 2009. Available from: http://www.legislation.gov.au/Details/C2007A00174
Communicable Diseases Network Australia. Surveillance Case Definitions for the Australian National Notifiable Diseases Surveillance System. 2004. Accessed on 25 June 2012. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/cdna-casedefinitions.htm
Australian Bureau of Statistics. 3101.0 – Australian Demographic Statistics, Jun 2013. Australian Bureau of Statistics; 2013.
Communicable Diseases Network Australia. Australian national notifiable diseases case definitions–Pneumococcal disease (invasive) case definition. 2004. Accessed on 27 March 2010. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_pnuemo.htm
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases. Significant events in pneumococcal vaccination practice in Australia. 2013. Accessed on 21 January 2014. This document was available from: www.ncirs.edu.au/immunisation/history/Pneumococcal-history-December-2013.pdf at the time of writing.
Turnidge JD, Bell JM, Collignon PJ. Rapidly emerging antimicrobial resistances in Streptococcus pneumoniae in Australia. Med J Aust 1999;170(4):152–155.
Miller E, Andrews N, Waight P, Slack M, George R. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011;11(10):760–768.
Pilishvili T, Lexau C, Farley M, Hadler J, Harrison L, Bennett N, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine J Infect Dis 2010;201(1):32–41.
Nahm MH, Lin J, Finkelstein JA, Pelton SI. Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis 2009;199(3):320–325.
Cooper D, Yu X, Sidhu M, Nahm MH, Ferstein P, Jansen KU. The 13-valent pneumococcal vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 2011;29(41):7207–7211.
Park IH Moore MR, Treanor JJ, Pelton SI, Pilishvili T, Beall B, et al. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 2008;198(12):1818–1822.
Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 2010;16(3):217–225.
Hsieh YC, Lin TL, Chang KY, Huang YC, Chen CJ, Lin TY, et al. Expansion and evolution of Streptococcus pneumoniae serotype 19A ST320 clone as compared to its ancestral clone, Taiwan19F-14 (ST236). J Infect Dis 2013;208(2):203–210.
Ricketson LJ, Vanderkooi OG, Wood ML, Leal J, Kellner JD. Clinical features and outcomes of serotype 19A invasive pneumococcal disease in Calgary, Alberta. Can J Infect Dis Med Microbiol 2014;25(2):e71–e75.
Ahl J, Littorin N, Forsgren A, Odenholt I, Resman F, Riesbeck K. High incidence of septic shock caused by Streptococcus pneumoniae serotype 3—a retrospective epidemiological study. BMC Infect Dis 2013;13:492.
Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 2009;199(6):776–785.
Reinert RR. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin Microbiol Infect 2009;15(Suppl. 3):7–11.
Hanquet G, Kissling E, Fenoll A, George R, Lepoutre A, Lernout T, et al. Pneumococcal serotypes in children in 4 European countries. Emerg Infect Dis 2010;16(9):1428–1439.
Dagan R. Serotype replacement in perspective. Vaccine 2009;27(Suppl 3):C22–C24.
Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011;378(9807):1962–1973.
European Centre for Disease Prevention and Control. Surveillance of invasive pneumococcal disease in Europe, 2010. Stockholm; 2012.
Downloads
Published
How to Cite
License
Copyright (c) 2015 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
